Last reviewed · How we verify
Antiasthmatic
Antiasthmatic is a Small molecule drug developed by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. It is currently in Phase 2 development. Also known as: biologics.
Antiasthmatic agents, such as those studied in ClinicalTrials.gov, are drugs that aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients. These agents, which can be small molecule drugs like Fasitibant, aim to reduce asthma exacerbation frequencies and related hospital visits.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Antiasthmatic |
|---|---|
| Also known as | biologics |
| Sponsor | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Sublingual Atropine Bioequivalence by Route of Administration (SABER) (PHASE1)
- Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS) (PHASE4)
- Expanded Access Protocol for Patients With Eosinophilic Esophagitis
- A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma (PHASE2)
- 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3) (PHASE3)
- Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia (PHASE2)
- Transporter Mediated Uptake of Montelukast (NA)
- Genotype Stratified Pharmacokinetic Study of Montelukast (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiasthmatic CI brief — competitive landscape report
- Antiasthmatic updates RSS · CI watch RSS
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz portfolio CI
Frequently asked questions about Antiasthmatic
What is Antiasthmatic?
Who makes Antiasthmatic?
Is Antiasthmatic also known as anything else?
What development phase is Antiasthmatic in?
Related
- Manufacturer: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz — full pipeline
- Therapeutic area: All drugs in Respiratory
- Also known as: biologics
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing